Brean Capital reiterated its Sell rating on Rockwell Medical Inc (NASDAQ: RMTI) on Monday following the FDA approval of its Triferic iron replacement product.
The firm maintained a $4 price target.
Analysts Jonathan Aschoff and Yi Cheng...
Rockwell Medical has overcome some hard questions and lingering doubts about its iron-replacement drug for dialysis patients, winning a long-sought FDA approval for Triferic and providing the biotech a green light to begin its marketing campaign.
Companies in this industry provide dialysis services to patients with diabetes. These companies make a substantial portion of their revenue from prescribing diabetes drugs. They also heavily dependent on Medicare and Medicaid.